Cycloserine resistance among drug-resistant tuberculosis cases in Taiwan
Open Access
- 1 July 2025
- journal article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (7) , e0342224
Abstract
Cycloserine (CS) is a widely used drug for drug-resistant tuberculosis (DR-TB) treatment. The World Health Organization (WHO) recently suggested a critical concentration (CC) for CS using the MGIT 960 system (MGIT). To strengthen our DR-TB management program, we performed CS resistance analyses to provide comprehensive drug susceptibility testing (DST). This retrospective study included Mycobacterium tuberculosis complex (MTBC) isolates obtained from 114 rifampin-resistant (RR) and multidrug-resistant (MDR) TB cases. We compared the results of phenotypic DST (pDST) and genotypic DST (gDST) and evaluated the minimum inhibitory concentration (MIC) using both MGIT and the Sensititre MYCOTB MIC Plate (Sensititre). Sanger sequencing and whole-genome sequencing were conducted to analyze the mutations of CS-resistant-associated ald and alr genes. Our results indicated that the optimal consistency with gDST was achieved with the CC of 16 µg/mL for MGIT, which aligns with the WHO recommendations, and the CC of 8 µg/mL for Sensititre. Of the 114 MTBC isolates, we found 5 (4.4%) CS-MGIT-resistant isolates, which all harbored mutations in the alr gene, including three previously known mutations M343T, T20M, L113R, and a novel mutation R243S, whereas seven low-MIC isolates harboring alr Q30R mutations might not be associated with CS resistance. Notably, M1I, E118K, and A184T in the ald gene and L113R, R243S, S261N, and M343T in the alr gene were predicted to have a destabilizing effect, which could interfere with protein functions and induce drug resistance. For accurate routine diagnosis of CS susceptibility, we adopted the CC of 16 µg/mL and suggested an interim 8 µg/mL using MGIT and Sensititre, respectively. IMPORTANCE: To strengthen the DR-TB management program in Taiwan, we performed cycloserine (CS) resistance analyses to enhance treatment outcomes. Of the 114 drug-resistant tuberculosis (DR-TB) isolates, we found 5 (4.4%) CS-MGIT-resistant isolates, with four isolates classified as multidrug-resistant (MDR)-TB and one isolate as Pre-XDR-TB. In addition, we observed all CS-MGIT-resistant isolates harbored mutations in the alr gene, including three previously known high-confidence mutations M343T, T20M, and L113R, as well as the novel R243S mutation. We also found that mutations could lead to CS resistance by disrupting protein stability.Keywords
Funding Information
- MOHW | Taiwan Centers for Disease Control (MOHW109-CDC-C-315-114403,MOHW110-CDC-C-315-11440,MOHW111-CDC-C- 315-124305,MOHW112-CDC-C-315-134305)
This publication has 22 references indexed in Scilit:
- Minimum inhibitory concentration of cycloserine against Mycobacterium tuberculosis using the MGIT 960 system and a proposed critical concentrationInternational Journal of Infectious Diseases, 2022
- Characterisation of drug-resistant Mycobacterium tuberculosis mutations and transmission in PakistanScientific Reports, 2022
- DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutationsProtein Science, 2020
- d-Cycloserine destruction by alanine racemase and the limit of irreversible inhibitionNature Chemical Biology, 2020
- Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypesNature Communications, 2019
- d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian DealClinical Infectious Diseases, 2018
- Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosisScientific Reports, 2018
- Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 2017
- Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistanceNature Genetics, 2016
- mCSM: predicting the effects of mutations in proteins using graph-based signaturesBioinformatics, 2013